DK2473636T3 - Type 1-interferondiagnostik - Google Patents

Type 1-interferondiagnostik Download PDF

Info

Publication number
DK2473636T3
DK2473636T3 DK10814513.7T DK10814513T DK2473636T3 DK 2473636 T3 DK2473636 T3 DK 2473636T3 DK 10814513 T DK10814513 T DK 10814513T DK 2473636 T3 DK2473636 T3 DK 2473636T3
Authority
DK
Denmark
Prior art keywords
ifna
ifn
rsad2
ifi44l
ifi44
Prior art date
Application number
DK10814513.7T
Other languages
English (en)
Inventor
Wei Zhu
Chris Morehouse
Barbara White
Bahija Jallal
Yihong Yao
Brandon Higgs
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Application granted granted Critical
Publication of DK2473636T3 publication Critical patent/DK2473636T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Claims (14)

1. Fremgangsmåde til identificering af en person, der er egnet til behandling af lupus med et anti-interferon-alfa-antistof eller et anti-interferon-alfa-receptor-antistof, der modulerer type 1-interferonaktivitet, som omfatter påvisning af et forhøjet niveau af mRNA af en gruppe af gener, der består af IFI27, IFI44, IFI44L og RSAD2, i en prøve fra personen, hvor en gennemsnitlig gange ændring i mRNA'et af gruppen af gener på mindst 4 gange indikerer, at en person er egnet til behandling af lupus med antistoffet, hvor stigningen er i forhold til a) niveauet i en prøve fra et væv eller en person, der ikke har sygdommen, eller b) ekspressionen af et eller flere kontrolgener.
2. Fremgangsmåde ifølge krav 1, hvor anti-interferon- antistoffet er sifalimumab.
3. Fremgangsmåde ifølge krav 1, hvor anti-interferon- antistoffet ikke er sifalimumab.
4. Fremgangsmåde ifølge krav 1, hvor påvisning af mRNA af IFI27, IFI44, IFI44L og RSAD2 omfatter a) isolering af RNA fra en prøve opnået fra personen; b) syntetisering af cDNA fra RNA'et; c) hybridisering af cDNA'et med oligonukleotider, der hybridiserer til nukleinsyresekvenser ifølge SEQ ID NO: 25 til 28 og 32; og d) amplificering af cDNA'et og påvisning af de amplificerede produkter.
5. Fremgangsmåde ifølge krav 4, hvor oligonukleotiderne er udvalgt blandt oligonukleotider med sekvenserne ifølge SEQ ID NO: 13 til 24.
6. Anti-interferon-alfa-antistof eller anti-interferon-alfa-receptor-antistof, der modulerer type 1-interferonaktivitet, til anvendelse til behandling af lupus hos en egnet person, hvor personen, der er egnet til behandling, identificeres ved påvisning af et forhøjet niveau af mRNA af en gruppe af gener, der består af IFI27, IFI44, IFI44L og RSAD2, i en prøve fra personen, hvor en gennemsnitlig gange ændring i mRNA'et af gruppen af gener på mindst 4 gange indikerer, at en person er egnet til behandling af lupus, hvor stigningen er i forhold til a) niveauet i en prøve fra et væv eller en person, der ikke har sygdommen, eller b) ekspressionen af et eller flere kontrolgener.
7. Antistof til anvendelse ifølge krav 6, hvor anti- interferon-antistoffet er sifalimumab.
8. Antistof til anvendelse ifølge krav 6, hvor anti- interferon-antistoffet ikke er sifalimumab.
9. Antistof til anvendelse ifølge krav 6, hvor påvisning af mRNA'et af IFI27, IFI44, IFI44L og RSAD2 omfatter a) isolering af RNA fra en prøve opnået fra personen; b) syntetisering af cDNA fra RNA'et; c) hybridisering af cDNA'et med oligonukleotider, der hybridiserer til nukleinsyresekvenser ifølge SEQ ID NO; 25 til 28 og 32; og d) amplificering af cDNA'et og påvisning af de amplificerede produkter.
10. Antistof til anvendelse ifølge krav 9, hvor oligonukleotiderne er udvalgt blandt oligonukleotider med sekvenserne ifølge SEQ ID NO: 13 til 24.
11. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 5 eller antistof til anvendelse ifølge et hvilket som helst af kravene 6 til 10, hvor det forhøjede niveau af mRNA er i forhold til puljede prøver fra raske personer.
12. Fremgangsmåde ifølge et hvilket som helst af kravene lb) eller 2 til 5 eller 11 i den udstrækning kravene 2 til 5 og 11 henviser tilbage til krav lb) eller antistof til anvendelse ifølge et hvilket som helst af kravene 6b) eller 7 til 11 i den udstrækning krav 7 til 11 henviser tilbage til krav 6b) , hvor kontrolgenerne er udvalgt blandt ACTB, GAPDH og 18S-rRNA.
13. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 5, 11 eller 12 eller antistof til anvendelse ifølge et hvilket som helst af kravene 6 til 12, hvor prøven er fuldblod eller serum.
14. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 5 eller 11 til 13 eller antistof til anvendelse ifølge et hvilket som helst af kravene 6 til 13, hvor personen har brug for behandling af systemisk lupus erythematosus.
DK10814513.7T 2009-09-03 2010-09-02 Type 1-interferondiagnostik DK2473636T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23963009P 2009-09-03 2009-09-03
PCT/US2010/047721 WO2011028933A1 (en) 2009-09-03 2010-09-02 Type 1 interferon diagnostic

Publications (1)

Publication Number Publication Date
DK2473636T3 true DK2473636T3 (da) 2017-02-06

Family

ID=43649646

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10814513.7T DK2473636T3 (da) 2009-09-03 2010-09-02 Type 1-interferondiagnostik

Country Status (23)

Country Link
US (3) US20120251546A1 (da)
EP (1) EP2473636B1 (da)
JP (2) JP5727484B2 (da)
KR (1) KR20120101340A (da)
CN (1) CN102753704A (da)
AU (1) AU2010289383B2 (da)
BR (1) BR112012004781A2 (da)
CA (1) CA2772921A1 (da)
CY (1) CY1118566T1 (da)
DK (1) DK2473636T3 (da)
ES (1) ES2613055T3 (da)
HR (1) HRP20170091T1 (da)
HU (1) HUE032917T2 (da)
LT (1) LT2473636T (da)
ME (1) ME02599B (da)
MX (1) MX2012002640A (da)
PL (1) PL2473636T3 (da)
PT (1) PT2473636T (da)
RS (1) RS55641B1 (da)
RU (1) RU2012112802A (da)
SI (1) SI2473636T1 (da)
SM (1) SMT201700063B (da)
WO (1) WO2011028933A1 (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7629116B2 (en) * 2002-06-11 2009-12-08 Idaho Research Foundation Type I interferon-inducible proteins to detect viral infection
BRPI0720035A2 (pt) * 2006-12-06 2019-05-07 Medimmune, Llc métodos para tratar um paciente tendo uma doença ou distúrbio, para tratar um paciente com doença autoimune, para neutralizar um perfil de expressão do marcador pd indutível por ifn do tipo 1 ou ifnalfa em um paciente, para monitorar ou prognosticar progressão de doença autoimune de um paciente, para monitorar a progressão da doença de um paciente que recebe o tratamento com um agente terapêutico que liga-se a e modula a atividade de ifnalfa, para identificar um paciente como um candidato para um agente terapêutico que liga-se a e modula a atividade de ifnalfa, para diagnosticar um paciente como tendo um distùrbio associado com níveis aumentados de ifnalfa, para identificar um terapêutico candidato para o tratamento de distùrbios mediados por ifnalfa e para detectar atividade de ifn em uma amostra, conjunto de sondas, e, kit
JP5411129B2 (ja) * 2007-05-03 2014-02-12 メディミューン，エルエルシー インターフェロンα誘導性薬力学的マーカー
US20140056889A1 (en) * 2011-04-26 2014-02-27 Genentech, Inc. Compositions and method for treating autoimmune diseases
WO2013101771A2 (en) * 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
CN108310375A (zh) * 2012-06-13 2018-07-24 米迪缪尼有限公司 针对抗i型干扰素受体（ifnar）抗体的固定剂量方案
JP6531306B2 (ja) * 2015-02-20 2019-06-19 一三 西野 炎症性筋疾患鑑別マーカー及びそれを用いた炎症性筋疾患と非炎症性筋疾患の鑑別方法
CN105316404B (zh) * 2015-02-27 2017-02-22 中南大学湘雅二医院 ***性红斑狼疮生物标志物及其诊断试剂盒
BR112018067951A2 (pt) 2016-03-10 2019-02-05 Viela Bio Inc moléculas que se ligam a ilt7 e métodos de uso destas
CN105567861B (zh) * 2016-03-16 2018-12-14 宫蕊 Ifi27作为冠心病诊断标志物的用途
JP7522749B2 (ja) * 2019-02-15 2024-07-25 アストラゼネカ・アクチエボラーグ Ｉ型インターフェロン媒介性障害
EP4058060A1 (en) 2019-11-11 2022-09-21 Astrazeneca AB Type i interferon inhibition in systemic lupus erythematosus
CN115667309A (zh) 2020-05-29 2023-01-31 阿斯利康(瑞典)有限公司 使用i型干扰素信号传导的抑制剂治疗心血管代谢疾病
TW202237647A (zh) 2020-10-08 2022-10-01 瑞典商阿斯特捷利康公司 狼瘡發作之治療
IL302871A (en) 2020-11-18 2023-07-01 Astrazeneca Ab Saving steroids
MX2023012465A (es) 2021-04-23 2024-04-04 Astrazeneca Ab Regimen de dosificacion de anti-ifnar1 para inyeccion subcutanea.
EP4192882A1 (en) 2021-04-23 2023-06-14 Astrazeneca AB Treatment of lupus nephritis with anti-type i inf receptor antibody anifrolumab
KR20240000557A (ko) 2021-04-23 2024-01-02 아스트라제네카 아베 피부 홍반 루푸스의 치료
JP2024516698A (ja) * 2021-05-04 2024-04-16 ビエラ バイオ インコーポレイテッド Ｉｌｔ７結合タンパク質を使用する、自己免疫疾患の治療方法
AU2022274306A1 (en) 2021-05-12 2023-11-23 Astrazeneca Ab Inhibitor of type 1 interferon receptor steroid sparing in systemic lupus erythematosus patients
AU2022317215A1 (en) 2021-07-27 2024-02-29 Astrazeneca Ab Treatment of lupus
AU2022359684A1 (en) 2021-10-04 2024-05-09 Astrazeneca Ab Treatment of lupus
WO2024056631A1 (en) 2022-09-14 2024-03-21 Idorsia Pharmaceuticals Ltd S1p 1 receptor modulators for use in the treatment of type 1 ifn mediated diseases
WO2024079241A1 (en) 2022-10-13 2024-04-18 Astrazeneca Ab Treatment of lupus

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8303165D0 (en) 1983-02-04 1983-03-09 Secher D S Monoclonal antibody
JPS60500864A (ja) 1983-02-04 1985-06-06 ワドリ、テクナラジズ、インコーパレイティド 近縁関係にあるが別個のタンパク質間に存在する共通決定基に対して特異的なハイブリド−マ抗体の製造および特性づけ
DE3306060A1 (de) 1983-02-22 1984-08-23 Boehringer Ingelheim International GmbH, 6507 Ingelheim Neue immunglobulin-produzierende hybridzellinien, deren verwendung und verfahren zu deren herstellung
EP0205404B1 (en) 1985-06-11 1992-07-15 Ciba-Geigy Ag Hybrid interferons
US7247425B2 (en) * 1998-01-30 2007-07-24 Evolutionary Genomics, Llc Methods to identify polynucleotide and polypeptide sequences which may be associated with physiological and medical conditions
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
WO2005051988A2 (en) * 2003-03-03 2005-06-09 Genentech, Inc. Compositions and methods for the treatment of systemic lupus erythematosis
CA2458085A1 (en) * 2003-03-21 2004-09-21 F. Hoffmann-La Roche Ag Transcriptional activity assay
CA2523142A1 (en) 2003-04-23 2004-11-04 Medarex, Inc. Humanized antibodies to interferon alpha receptor-1 (ifnar-1)
AU2004299833B2 (en) 2003-12-10 2009-05-07 E. R. Squibb & Sons, L.L.C. Interferon alpha antibodies and their uses
EP1730308A4 (en) * 2004-03-05 2008-10-08 Rosetta Inpharmatics Llc CLASSIFICATION OF PATIENTS OF BREAST CANCER USING A COMBINATION OF CLINICAL CRITERIA AND GENETIC INFORMATIVE SETS
EP2662390B1 (en) 2004-06-21 2017-08-02 E. R. Squibb & Sons, L.L.C. Interferon alpha receptor 1 antibodies and their uses
PT2327792E (pt) * 2005-08-05 2013-11-21 Genentech Inc Métodos e composições para a detecção de distúrbios autoimunes
US8211649B2 (en) * 2006-03-31 2012-07-03 Human Genome Sciences, Inc. Methods of diagnosing and prognosing hodgkin's lymphoma
US20100120627A1 (en) * 2006-08-02 2010-05-13 Abdelmajid Belouchi Genemap of the human genes associated with psoriasis
BRPI0720035A2 (pt) * 2006-12-06 2019-05-07 Medimmune, Llc métodos para tratar um paciente tendo uma doença ou distúrbio, para tratar um paciente com doença autoimune, para neutralizar um perfil de expressão do marcador pd indutível por ifn do tipo 1 ou ifnalfa em um paciente, para monitorar ou prognosticar progressão de doença autoimune de um paciente, para monitorar a progressão da doença de um paciente que recebe o tratamento com um agente terapêutico que liga-se a e modula a atividade de ifnalfa, para identificar um paciente como um candidato para um agente terapêutico que liga-se a e modula a atividade de ifnalfa, para diagnosticar um paciente como tendo um distùrbio associado com níveis aumentados de ifnalfa, para identificar um terapêutico candidato para o tratamento de distùrbios mediados por ifnalfa e para detectar atividade de ifn em uma amostra, conjunto de sondas, e, kit
JP5411129B2 (ja) * 2007-05-03 2014-02-12 メディミューン，エルエルシー インターフェロンα誘導性薬力学的マーカー
US20100209914A1 (en) * 2007-05-25 2010-08-19 Ore Pharmaceuticals , Inc. Methods, systems, and kits for evaluating multiple sclerosis
ES2529593T3 (es) * 2008-02-08 2015-02-23 Medimmune, Llc Marcadores de enfermedades y usos de los mismos
JP2011519551A (ja) * 2008-04-21 2011-07-14 ノバルティス・フォルシュングスシュティフトゥング・ツヴァイクニーダーラッスング・フリードリッヒ・ミーシェー・インスティトゥート・フォー・バイオメディカル・リサーチ 抗ウイルス治療
WO2009149319A2 (en) * 2008-06-05 2009-12-10 Wyeth Gene expression profiles associated with asthma exacerbation attacks

Also Published As

Publication number Publication date
US20160024205A1 (en) 2016-01-28
JP5727484B2 (ja) 2015-06-03
MX2012002640A (es) 2012-06-25
AU2010289383A1 (en) 2012-04-19
EP2473636B1 (en) 2016-10-26
US20150191788A1 (en) 2015-07-09
LT2473636T (lt) 2017-02-10
JP2015147788A (ja) 2015-08-20
SMT201700063B (it) 2017-03-08
BR112012004781A2 (pt) 2017-02-14
US20120251546A1 (en) 2012-10-04
CA2772921A1 (en) 2011-03-10
HRP20170091T1 (hr) 2017-03-24
HUE032917T2 (hu) 2017-11-28
CY1118566T1 (el) 2017-07-12
CN102753704A (zh) 2012-10-24
WO2011028933A1 (en) 2011-03-10
RS55641B1 (sr) 2017-06-30
PT2473636T (pt) 2017-02-06
KR20120101340A (ko) 2012-09-13
ME02599B (me) 2017-06-20
PL2473636T3 (pl) 2017-05-31
EP2473636A1 (en) 2012-07-11
AU2010289383B2 (en) 2015-04-16
EP2473636A4 (en) 2013-02-27
SI2473636T1 (sl) 2017-04-26
ES2613055T3 (es) 2017-05-22
JP2013503642A (ja) 2013-02-04
RU2012112802A (ru) 2013-10-10

Similar Documents

Publication Publication Date Title
DK2473636T3 (da) Type 1-interferondiagnostik
JP5411129B2 (ja) インターフェロンα誘導性薬力学的マーカー
KR101532797B1 (ko) 인터페론 알파 유도성 약력학적 마커
EP2252703B1 (en) Disease markers and uses thereof
AU2016295347A1 (en) Gene signature for immune therapies in cancer
KR20150090246A (ko) 암을 위한 분자 진단 테스트
KR20140044341A (ko) 암에 대한 분자적 진단 검사
KR20160117606A (ko) 항-혈관형성 약물에 대한 반응 및 암의 예후를 예측하기 위한 분자적 진단 시험
JP2013526845A (ja) サイトカイン標的薬（ＣｙＴＤ）に対する、炎症性疾患に罹患している対象の初期応答または非応答を予測する遺伝子および遺伝子の組み合わせ
CN111630182A (zh) 用于治疗类风湿性关节炎(ra)的诊断和治疗方法
CN110740733A (zh) Irak4介导的疾患和病症的诊断和治疗方法
KR20170041955A (ko) 근위축성측삭경화증에 대한 진단 마커로서의 돌연변이 유전자 및 이를 이용한 진단방법
US20110046202A1 (en) Method for testing a subject thought to have or to be predisposed to asthma
US20100261172A1 (en) Interferon alpha-induced pharmacodynamic markers
KR101114033B1 (ko) 단일염기다형을 포함하는 폴리뉴클레오티드, 이를 포함하는 마이크로어레이 및 진단키트, 및 이를 이용한 분석방법
WO2009155559A1 (en) Interferon alpha-induced pharmacodynamic markers
WO2015010744A1 (en) Seronegative spondyloarthropathy diagnosis and treatment
NZ618191B2 (en) Molecular diagnostic test for cancer
AU2014200127A1 (en) Interferon alpha-induced pharmacodynamic markers